首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1544631

精神分裂症藥物市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Schizophrenia Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月09日 | 出版商:

Global Market Insights Inc. | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024年至2032年，全球精神分裂症藥物市場的複合年成長率將達到7.1%，這歸因於精神分裂症盛行率的增加，這需要有效的治療解決方案。藥理學研究的進步導致了新型抗精神病藥物的開發，這些藥物提高了療效並減少了副作用，使治療更易於管理並提高了患者的依從性。舉個例子，2023年4月，CHEPLAPHARM宣布從禮來公司收購Zyprexa(R)。該交易包括 Zyprexa(R) 及其各種形式的全球權利，從而增強了 CHEPLAPHARM 的精神分裂症和雙相情感障礙治療產品組合。

此外，人們對精神健康狀況的認知不斷提高，並消除了對其的污名化，導致診斷率提高，對治療方案的需求也隨之增加。醫療保健支出和精神健康基礎設施投資的增加透過促進創新療法和綜合護理的獲得進一步支持市場擴張。

精神分裂症藥物市場根據治療類別、類型、治療、配銷通路和地區進行分類。

從 2024 年到 2032 年，第三代抗精神病藥物領域將保持顯著的需求，因為與早期類別的抗精神病藥物相比，它們具有卓越的療效和有利的副作用。這些較新的藥物也稱為非典型抗精神病藥，具有顯著的優勢，例如降低錐體外症狀的風險以及降低體重增加和代謝問題的發生率。他們能夠更有效地管理精神分裂症的陽性和陰性症狀，再加上患者依從性和生活品質的提高，正在引領精神分裂症藥物的採用。

到 2032 年，青少年型精神分裂症部分將佔據顯著的市場佔有率，因為其獨特且往往嚴重的症狀，需要專門的治療方法。青少年型精神分裂症的特徵是行為失調、情緒反應不當和認知功能受損，為治療帶來了明顯的挑戰。對解決這些特定症狀的有效藥物的需求正在推動新藥物療法的開發和採用，從而有助於市場擴張。

受精神分裂症高盛行率和對有效治療解決方案需求增加的推動，北美精神分裂症藥物市場將在 2024 年至 2032 年間顯著成長。先進的醫療基礎設施和廣泛的醫療服務有利於早期診斷和治療，進一步支持市場成長。此外，提高認知並減少對精神健康狀況的恥辱會鼓勵更多人尋求治療，從而導致北美地區對精神分裂症藥物的需求不斷成長。

產業生態系統分析
產業影響力
- 成長動力
  - 精神分裂症盛行率增加
  - 藥物輸送系統的進步
  - 政府措施和支持
- 產業陷阱與挑戰
  - 藥物的副作用
  - 嚴格的監管場景
成長潛力分析
監管環境
技術景觀
- 核心技術
- 鄰近技術
未來市場趨勢
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按治療類別，2021 - 2032 年

主要趨勢
第二代抗精神病藥
第三代抗精神病藥
其他治療類

第 6 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
偏執型精神分裂症
青少年型精神分裂症
緊張性精神分裂症
未分化精神分裂症
其他類型

第 7 章：市場估計與預測：按處理方式，2021 - 2032

主要趨勢
口服
可注射

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Alkermes Public Limited Company
AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company
H. Lundbeck A/S
Intra-Cellular Therapies, Inc.
Johnson and Johnson
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Recordati Industria Chimica e Farmaceutica S.p.A
SUMITOMO PHARMA CO., LTD
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Vanda Pharmaceuticals Inc.

簡介目錄

Product Code: 10166

Global Schizophrenia Drugs Market will record a 7.1% CAGR from 2024 to 2032, attributed to an increase in the prevalence of schizophrenia, which necessitates effective treatment solutions. Advances in pharmacological research have led to the development of novel antipsychotic medications with improved efficacy and reduced side effects, making treatment more manageable and enhancing patient adherence. Citing an instance, in April 2023, CHEPLAPHARM announced the acquisition of Zyprexa(R) from Eli Lilly. The deal includes global rights to Zyprexa(R) and its various forms, enhancing CHEPLAPHARM's portfolio for schizophrenia and bipolar disorders treatment.

Additionally, growing awareness and de-stigmatization of mental health conditions are leading to higher diagnosis rates and greater demand for treatment options. The rise in healthcare expenditure and investment in mental health infrastructure further supports market expansion by facilitating access to innovative therapies and comprehensive care.

The schizophrenia drugs market is sorted based on therapeutic class, type, treatment, distribution channel, and region.

The third-generation antipsychotics segment will retain a notable demand from 2024 through 2032, because of their superior efficacy and favorable side effect profile compared to earlier classes of antipsychotics. These newer medications, also known as atypical antipsychotics, offer significant advantages such as reduced risk of extrapyramidal symptoms and lower incidence of weight gain and metabolic issues. Their ability to manage both positive and negative symptoms of schizophrenia more effectively, combined with improved patient adherence and quality of life, is ushering in the adoption of schizophrenia drugs.

By 2032, the hebephrenic schizophrenia segment will hold a remarkable market share, due to its unique and often severe symptomatology, which necessitates specialized treatment approaches. Characterized by disorganized behavior, inappropriate emotional responses, and impaired cognitive function, hebephrenic schizophrenia presents distinct challenges in management. The need for effective medications that address these specific symptoms is fueling the development and adoption of new drug therapies, aiding the market expansion.

North America schizophrenia drugs market will register a noteworthy growth rate between 2024 and 2032, propelled by a high prevalence of schizophrenia and amplified demand for effective treatment solutions. Advanced healthcare infrastructure and widespread access to medical services facilitate early diagnosis and treatment, further supporting market growth. Additionally, increasing awareness and reducing stigma around mental health conditions encourage more individuals to seek treatment, contributing to the rising demand for schizophrenia drugs across North America.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of schizophrenia
  - 3.2.1.2 Advancements in drug delivery systems
  - 3.2.1.3 Government initiatives and support
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Side effects of drugs
  - 3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Pipeline analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapeutic Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Second generation antipsychotics
5.3 Third generation antipsychotics
5.4 Other therapeutic classes

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Paranoid schizophrenia
6.3 Hebephrenic schizophrenia
6.4 Catatonic schizophrenia
6.5 Undifferentiated schizophrenia
6.6 Other types

Chapter 7 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa